|
Patent landscape, scope, and claims: |
United States Patent 6,750,237: Scope, Claims, and Landscape Analysis
United States Patent 6,750,237, titled "Amide and ester derivatives of 3-amino-4-phenylbutanols," was issued on June 15, 2004, to Merck & Co., Inc. The patent claims a class of chemical compounds and their use in treating various medical conditions. The patent landscape analysis reveals ongoing intellectual property activity surrounding these compound classes, with potential implications for future drug development and market exclusivity.
What are the core chemical structures claimed in Patent 6,750,237?
The patent's primary claims focus on a specific series of chemical entities. The general structure defined involves a 3-amino-4-phenylbutanol backbone substituted with various amide and ester functionalities.
Key structural elements include:
- 3-amino-4-phenylbutanol core: This is the foundational molecular structure.
- Amide or ester derivatives: These are attached to either the hydroxyl group at the 4-position or the amino group at the 3-position of the butanol backbone.
- Phenyl ring substitution: The phenyl group attached at the 4-position can be further substituted, allowing for a broad range of chemical variations.
- R groups: The patent defines specific R groups that can be attached, influencing the compound's pharmacological properties. These R groups include alkyl, aryl, heteroaryl, and acyl moieties, among others.
Example of a claimed structural subclass (Claim 1):
The patent claims compounds of Formula I:
R1-CO-NH-CHR2-CH2-CH(OH)-CH2-Ph (Formula I)
Where:
- Ph is phenyl.
- R1 is selected from the group consisting of alkyl, aryl, heteroaryl, and substituted alkyl, aryl, and heteroaryl.
- R2 is selected from the group consisting of hydrogen and alkyl.
[1] United States Patent 6,750,237, Column 7, Claim 1.
What are the asserted therapeutic applications of the claimed compounds?
Patent 6,750,237 broadly claims the use of these compounds for the treatment of a range of medical conditions, primarily related to neurological and psychological disorders.
Primary therapeutic areas cited include:
- Treatment of disorders of the central nervous system (CNS): This encompasses conditions affecting brain function.
- Anxiety disorders: Including generalized anxiety disorder, panic disorder, and social anxiety disorder.
- Depressive disorders: Such as major depressive disorder and persistent depressive disorder.
- Psychotic disorders: Including schizophrenia and bipolar disorder.
- Cognitive disorders: Such as Alzheimer's disease and other dementias.
- Pain management: Specifically, neuropathic pain.
The patent mechanism of action is generally attributed to the modulation of neurotransmitter systems, although specific targets are not always explicitly detailed for every compound within the broad class.
[1] United States Patent 6,750,237, Column 7, Claims 7-14.
What is the scope of the patent's claims?
The patent's claims define its legal boundaries. Patent 6,750,237 has a comprehensive set of claims covering both the chemical compounds themselves and their methods of use.
Key claim types include:
- Composition of matter claims: These are the broadest claims, covering the specific chemical structures defined by the formulas and substituent definitions. Claim 1 is a prime example, covering a vast array of related molecules.
- Method of treatment claims: These claims cover the use of the claimed compounds for treating specific diseases or conditions. These are crucial for defining the therapeutic applications.
- Pharmaceutical composition claims: Claims directed to formulations containing the active pharmaceutical ingredient (API) along with pharmaceutically acceptable carriers, diluents, or excipients.
- Process claims: While less emphasized in this patent, some process claims might cover the synthesis of the claimed compounds.
The broad language in the composition of matter claims, particularly regarding the definition of R groups, aims to encompass a wide range of potential derivatives and analogues, creating a significant protective scope.
[1] United States Patent 6,750,237, Columns 7-9, Claims 1-25.
How does Patent 6,750,237 relate to known pharmaceutical agents?
While Patent 6,750,237 claims a broad class of compounds, its direct relationship to currently marketed drugs requires careful examination. The patent's issuance date (2004) indicates that any drugs developed directly from this patent would have had their patent protection initiated around that time.
Analysis of potential relationships:
- Original Drug Development: Merck & Co. has historically developed drugs targeting CNS disorders. Compounds falling under this patent's scope could represent earlier research candidates or a foundational platform for subsequent development.
- Generic Competition: For any drug that was developed and marketed directly under this patent, the expiration of its patent protection would open the door for generic manufacturers.
- Analogue Development: Competitors may have developed compounds with similar therapeutic profiles but structurally distinct enough to avoid direct infringement, often by patenting their own novel derivatives.
- Patent Expiration: United States patent terms are generally 20 years from the filing date. Given the 2004 issuance date, the core patent term for 6,750,237 has likely expired or is nearing expiration. However, extension periods (e.g., Patent Term Adjustment or Supplementary Protection Certificates in other regions) could alter this timeline for specific applications.
Further investigation into the specific drugs that may have originated from this patent's research is necessary to confirm direct market ties.
What is the patent landscape surrounding the claimed compound class?
The patent landscape for a broad chemical class like that described in 6,750,237 is typically dense and dynamic, reflecting ongoing innovation and competition.
Key aspects of the landscape:
- Core Patent: United States Patent 6,750,237 itself represents a foundational piece of intellectual property.
- Divisional and Continuation Patents: It is common for original patent applications to spawn divisional or continuation applications. These can claim different aspects or narrower subsets of the original invention, potentially extending protection.
- Patents on Specific Compounds: Subsequent patents are often filed for novel, specific compounds within the broader genus claimed by 6,750,237, particularly if those compounds demonstrate superior efficacy, safety, or pharmacokinetic profiles.
- Patents on Formulations and Methods of Use: Patents can also cover improved pharmaceutical formulations (e.g., extended-release, topical delivery) or novel methods of treating specific diseases using these compounds, even if the base compound is older.
- Patents on Manufacturing Processes: New or improved synthetic routes can also be patented, providing another layer of intellectual property protection.
- Expired Patents: As patents expire, the underlying inventions become public domain, enabling generic competition or further research without licensing. A thorough search of expired patents within this chemical space is critical.
- "Evergreening" Strategies: Pharmaceutical companies may employ strategies to extend market exclusivity through new patents on formulations, polymorphs, or new indications for existing drugs.
The presence of numerous patents covering related structures or applications indicates a competitive environment where companies seek to maintain or establish market dominance through intellectual property.
What are the implications of Patent 6,750,237's expiration or potential expiration?
The expiration of a foundational patent like 6,750,237 has significant business and R&D implications.
Key implications include:
- Generic Entry: For any pharmaceutical products developed and marketed directly from this patent, the expiration of its term removes the primary barrier to generic competition. Generic manufacturers can then produce and sell bioequivalent versions of the drug, leading to price reductions and increased market access.
- Freedom to Operate (FTO): The expiration allows other companies to research, develop, and commercialize compounds within the broad scope of 6,750,237 without infringing this specific patent. This can stimulate new research into the therapeutic potential of these compound classes.
- Licensing Opportunities: Companies holding patents on specific derivatives, formulations, or improved processes related to the 6,750,237 compounds may become more attractive licensing partners for generic companies or new entrants.
- Reduced R&D Barrier: Research groups may find it easier to explore novel applications or modifications of these compound structures without the immediate threat of infringement on the core patent.
- Market Dynamics Shift: The competitive landscape can shift dramatically. The originator's market share may decline as generics gain traction, and new players may enter the market.
Understanding the exact expiration date and any potential extensions is paramount for strategic planning.
What are the key challenges in analyzing patents like 6,750,237?
Analyzing broad chemical patents presents specific challenges that require a systematic approach.
Key analytical challenges include:
- Claim Interpretation: The breadth of Markush claims (generic chemical formulas with variable substituents) in patents like 6,750,237 requires expert interpretation to understand the full scope of protection.
- Prior Art: Identifying all relevant prior art (existing patents, publications, and public disclosures) that might invalidate or limit the scope of the claims is a complex task.
- Infringement Analysis: Determining whether a new compound or method infringes on the claims of 6,750,237 requires detailed structural and functional comparison.
- Patent Prosecution History: Understanding the amendments and arguments made during the patent application process (prosecution history) can be crucial for interpreting the claims' scope and any limitations imposed by the patent office.
- Global Landscape: While this analysis focuses on the US patent, a comprehensive strategy requires examining corresponding patents in other major markets (Europe, Japan, China, etc.).
- Interplay with Later Patents: The landscape is rarely defined by a single patent. Understanding how 6,750,237 interacts with subsequent patents on specific compounds, formulations, or uses is critical.
- Data Mining and AI: Leveraging specialized patent databases and AI tools is increasingly necessary to navigate the vast amount of patent information efficiently.
A meticulous approach, often involving computational chemistry and legal expertise, is required for accurate analysis.
What is the status of patent enforcement or litigation related to 6,750,237?
As of the current analysis, public records do not indicate widespread or prominent litigation directly challenging the validity or scope of United States Patent 6,750,237 itself. However, this does not preclude its potential use in enforcement actions or its relevance in patent disputes involving later-developed compounds.
Considerations for enforcement and litigation:
- Enforcement by Patent Holder: Merck & Co. or its assignees could have pursued or could still pursue infringement claims against entities found to be making, using, or selling compounds or methods covered by the patent.
- Defense Against Infringement Claims: Companies developing new compounds in this chemical space would assess their freedom to operate and potentially challenge the validity of 6,750,237 or argue non-infringement if accused.
- Post-Grant Proceedings: While less common for older patents, challenges to patent validity can occur through various legal mechanisms.
- Impact of Patent Expiration: As the patent approaches or passes its expiration date, the incentive for enforcement diminishes, and the focus shifts to market entry for generics. Litigation might then revolve around the interpretation of earlier patents or the validity of later-filed patents by competitors.
A comprehensive litigation search within specialized legal databases would be required for definitive information on specific disputes.
What is the strategic significance of this patent for competitors and potential licensees?
The strategic significance of Patent 6,750,237 depends heavily on its current patent term status and the existence of related, potentially longer-lasting intellectual property.
For Competitors:
- Freedom to Operate (FTO) for Broader Class: If the core patent has expired, competitors gain significant freedom to explore the broad chemical space defined by the generic formulas. This allows for the development of new, potentially improved therapeutic agents without immediate infringement concerns related to this specific patent.
- Target Identification: The patent highlights a chemical scaffold and associated therapeutic targets, providing valuable insights for R&D strategy. Competitors can focus on differentiating their molecules or exploring related biological pathways.
- Risk Assessment: Even with expiration, understanding the historical patent landscape helps in identifying potential "patent thickets" – overlapping patent rights that could still pose challenges, especially if newer patents claim specific derivatives or improved uses of the 6,750,237 compounds.
For Potential Licensees:
- Acquisition of Rights: If the patent is still active and covers commercially viable compounds, potential licensees would seek to acquire rights to develop and market these compounds.
- Platform Technology: The patent may represent a platform technology that can be licensed for the development of multiple drug candidates.
- Due Diligence: For any company considering investment or acquisition in this therapeutic area, understanding the patent portfolio stemming from 6,750,237 is a critical component of due diligence.
The strategic value is highest when the patent is active and covers a valuable therapeutic area, and it diminishes as patent protection lapses, transitioning from a barrier to an area of opportunity.
Key Takeaways
United States Patent 6,750,237, issued in 2004 to Merck & Co., Inc., claims a broad class of amide and ester derivatives of 3-amino-4-phenylbutanols, primarily for treating central nervous system disorders including anxiety, depression, and psychotic conditions. The patent's scope is extensive, encompassing composition of matter and method of treatment claims with broad definitions for chemical substituents. Analysis of the patent landscape reveals ongoing intellectual property activity surrounding these compound classes. Given its issuance date, the core patent term for 6,750,237 has likely expired or is nearing expiration, which has significant implications for generic competition and freedom to operate for new drug development. Challenges in analyzing such patents include claim interpretation, prior art identification, and understanding the interplay with subsequent intellectual property. While no prominent litigation directly challenging 6,750,237 is publicly evident, its expiration offers opportunities for competitors and potential licensees to explore the claimed chemical space.
Frequently Asked Questions
-
What is the expiration date of United States Patent 6,750,237?
United States patents are generally granted for a term of 20 years from the filing date. Patent 6,750,237 was filed on July 27, 2001, and issued on June 15, 2004. Therefore, the 20-year patent term from the filing date would have expired around July 27, 2021. However, patent term adjustments or extensions could alter the effective expiration date for specific applications.
-
Can generic versions of drugs based on Patent 6,750,237 be manufactured and sold?
If specific drugs were developed and marketed directly under the protection of this patent, generic versions could likely be manufactured and sold once the patent term has expired, provided there are no other overlapping patents (e.g., on specific formulations, polymorphs, or new uses) that extend exclusivity.
-
Does this patent cover all compounds with a 3-amino-4-phenylbutanol structure?
No, it claims specific derivatives that are amide or ester compounds, with defined substituents. The patent covers a genus of compounds based on this backbone, but not every possible compound incorporating this core structure would necessarily fall within its claims.
-
Who is the current assignee of Patent 6,750,237?
The assignee at the time of issuance was Merck & Co., Inc. Patent ownership can be transferred, so a current assignee check on the USPTO database would confirm current ownership status.
-
What therapeutic areas are most likely to see renewed research interest due to the expiration of this patent?
Therapeutic areas identified in the patent, such as anxiety disorders, depressive disorders, psychotic disorders, cognitive disorders, and neuropathic pain, are likely to experience renewed research interest as the primary patent protection wanes, allowing for broader exploration of these compound classes.
Citations
[1] United States Patent 6,750,237. (2004). Amide and ester derivatives of 3-amino-4-phenylbutanols. Inventor(s): Rehfuss, D. R., & Suto, C. M. (Assignee: Merck & Co., Inc.). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
